GUTS FRACTYL HEALTH, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1572616 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.5%
TTM net income YoY10.9%
TTM EPS YoY96.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin46.2%
Operating margin-100,571.0%
Net margin-73,864.5%
FCF margin-72,350.5%
EBITDA margin-99,843.0%
Returns
ROE—
ROA-74.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets73.7%
Debt / equity0.00x
Current ratio3.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue1,897.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $0 | $93,000 | $120,000 |
| Cost of revenue | $0 | $50,000 | $77,000 |
| Gross profit | $0 | $43,000 | $43,000 |
| R&D expense | $74.54M | $70.47M | $38.04M |
| SG&A expense | $22.28M | $23.10M | $12.84M |
| Operating income | -$96.82M | -$93.53M | -$50.84M |
| Income tax | $0 | $0 | $0 |
| Net income | -$140.95M | -$68.69M | -$77.09M |
| EBITDA | -$95.69M | -$92.85M | -$50.55M |
| EPS (basic) | -1.86 | -1.62 | -45.29 |
| EPS (diluted) | -1.86 | -1.62 | -45.29 |
| Weighted avg. shares (diluted) | 75.82M | 43.54M | 2.08M |
| Balance sheet | |||
| Cash & equivalents | $81.54M | $71.72M | $37.78M |
| Receivables | — | $0 | $22,000 |
| Inventory | — | $73,000 | $73,000 |
| Current assets | $87.58M | $71.76M | $35.65M |
| PP&E, net | $2.41M | $2.98M | $490,000 |
| Total assets | $121.40M | $108.08M | $76.21M |
| Current liabilities | $18.33M | $19.77M | $11.19M |
| Total liabilities | $111.94M | $79.65M | $113.94M |
| Shareholders' equity | $9.46M | $28.42M | -$325.06M |
| Shares outstanding | 12.78M | 48.76M | 2.11M |
| Cash flow statement | |||
| Operating cash flow | -$90.33M | -$65.52M | -$42.82M |
| Capital expenditure | $557,000 | $1.76M | $359,000 |
| Free cash flow | -$90.89M | -$67.29M | -$43.18M |
| Investing cash flow | -$557,000 | -$1.76M | -$359,000 |
| Financing cash flow | $104.96M | $101.23M | $27.44M |
| Depreciation & amortization | $1.13M | $677,000 | $286,000 |
| Stock-based compensation | $6.68M | $14.43M | $4.30M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.